Lomtegovimab

Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19[1][2].

Product Specifications

CAS Number

[2550869-33-3]

Product Name Alternative

BI 767551; DZIF-10c

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/lomtegovimab.html

Purity

99.94

Solubility

10 mM in DMSO

Smiles

[Lomtegovimab]

Molecular Weight

(145.58 kDa)

References & Citations

[1]Halwe S, et al. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Viruses. 2021 Jul 29;13 (8) :1498.|[2]Halwe S, et al. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Viruses. 2021 Jul 29;13 (8) :1498.